The Paired-domain Regulates DNA Binding by the Homeodomain within the Intact Pax-3 Protein*

(Received for publication, January 27, 1997, and in revised form, March 24, 1997)

D. Alan Underhill Dagger and Philippe Gros Dagger §

From the Dagger  Department of Biochemistry, McGill University, Montreal, Quebec, H3G 1Y6 Canada

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES


ABSTRACT

Pax-3 contains two structurally independent DNA-binding domains, a paired-domain and a homeodomain. Their functional interdependence has been suggested by the analysis of the Sp-delayed (Spd) mouse mutant, in which a glycine to arginine substitution at position 9 of the paired-domain abrogates DNA binding by both domains. This glycine is located in the beta -turn portion of a beta -hairpin motif, and the requirement for this structure was investigated by mutagenesis at this and neighboring positions. At position 9, only substitution with proline increased DNA binding by the paired-domain and homeodomain above the level observed with the Spd arginine mutation, suggesting that the beta -turn is necessary for the function of both DNA-binding domains. Alanine scanning mutagenesis also identified a number of flanking residues important for DNA binding by both domains, emphasizing the requirement of the beta -hairpin for the interaction of Pax-3 with DNA. Furthermore, we show that these mutations reduce binding by the homeodomain at the monomeric level and do not impair dimerization on a TAAT(N)2ATTA consensus motif. In contrast, the wild-type paired-domain was found to prevent dimerization on consensus motifs with 3-base pair spacing of the type TAAT(N)3ATTA. Importantly, both the deleterious effect of the Spd mutation on homeodomain DNA binding and the loss of dimerization on TAAT(N)3ATTA motifs can be transferred to a heterologous homeodomain from the human phox protein. Moreover, the presence of the paired-domain affects sequence discrimination within the 3-base pair spacer in this context. These analyses establish that the beta -hairpin motif is essential for paired-domain and homeodomain DNA binding, and suggest a novel mechanism by which the paired-domain can influence sequence specificity of the homeodomain within the Pax-3 polypeptide.


INTRODUCTION

The paired-domain was originally described as a region of sequence homology between the Drosophila segmentation gene paired and two genes encoded at the gooseberry locus (1), and was subsequently shown to have a DNA-binding function (2). In addition, paired (Prd)1 and the gooseberry gene products contain a second DNA-binding domain, the paired-type homeodomain. Both domains are conserved in the mammalian Pax-3, -4, -6, and -7 genes, while the remaining Pax genes contain only the paired-domain. Over the past several years, the importance of Pax transcription factors in regulating neurogenesis and somitogenesis has been established through the association of specific developmental disorders in both mice and humans with mutations in the Pax-1, Pax-3, and Pax-6 genes (3). In the case of Pax-3, alterations in this gene are responsible for the Splotch (Sp) mouse mutant (4) and human Waardenburg Syndrome (5, 6), both of which are characterized by pigmentary disturbances in the heterozygous state (7). Homozygous Sp embryos die in utero and display neural tube defects, dysgenesis of various neural crest cell lineages, and an absence of limb musculature (7, 8). In addition, chromosomal translocations involving the PAX-3 (9) and PAX-7 (10) genes have been implicated in the etiology of the human solid tumor alveolar rhabdomyosarcoma, consistent with the aberrant expression of some Pax genes in cellular transformation (11-13).

Both genetic and biochemical studies indicate that the paired-domain comprises two independent and interactive subdomains, NH2-terminal and COOH-terminal, that make distinct contributions to sequence recognition (14, 15). For instance, alternative use of a single glutamine codon in the Pax-3 paired-domain leads to the production of isoforms which differ in their ability to utilize the COOH-terminal subdomain for DNA binding (16). Likewise, an alternative splicing event in the PAX-6 gene encodes an isoform which recognizes DNA exclusively through its COOH-terminal subdomain (15). Adding to this diversity in sequence recognition, consensus sequences derived in vitro for the Prd homeodomain contain palindromic recognition motifs of the type TAAT(N)2-3ATTA to which two homeodomains bind cooperatively (17). Furthermore, regulation of the Drosophila even-skipped gene by Prd requires the cooperative binding of the paired-domain and homeodomain to a target sequence that contains juxtaposed recognition motifs for both domains (18). Consequently, although the paired-domain and homeodomain can bind DNA with high affinity when expressed separately, their presence in the same polypeptide allows them to cooperate in DNA recognition. It is not clear, however, if the DNA-binding properties of Pax proteins which contain both domains are simply determined by the sum of their parts or if interactions between the domains influence DNA recognition.

Our previous analysis of the mouse Spd mutation has suggested that the paired-domain and homeodomain of Pax-3 may functionally interact (19). In Spd, a single glycine to arginine substitution at the ninth position of the paired-domain abrogates DNA binding to both domains. The elucidation of the crystal structure for the paired-domain of the Drosophila Prd protein revealed that the glycine residue contributes to a beta -turn that joins 2 short anti-parallel beta -strands, together forming a beta -hairpin motif (20). To determine the specific requirement for the beta -turn and to define the role of the beta -hairpin motif in paired-domain and homeodomain DNA binding, additional mutagenesis was carried out at position 9 and the conserved residues that make up this structure. The current analysis reveals that the integrity of the beta -hairpin is essential for the DNA binding activity of both the paired-domain and homeodomain, confirming our original hypothesis that the homeodomain does not function as an independent globular structure within the intact Pax-3 protein. Importantly, sequence recognition by the homeodomain was found to differ in the presence or absence of the paired-domain in both Pax-3 and a chimeric protein containing a homeodomain derived from the human phox protein, indicating that the paired-domain of Pax-3 might influence the sequence specificity of the homeodomain in vivo.


EXPERIMENTAL PROCEDURES

Plasmid Construction

The construction of expression plasmids encoding wild-type Pax-3, Pax-3Spd (Pax-3R9) and Pax-3Delta prd has been previously described (19). The wild-type and Spd Pax-3 constructs comprise a portion of the Pax-3 cDNA that extends from nucleotides 297 to 1801 (21) cloned into the eukaryotic expression vector pMT2, allowing for expression in COS-7 cells. Both constructs encode the full-length 479-amino acid Pax-3 polypeptide and differ by the presence of a glycine (wild-type) or an arginine (Spd) residue at the ninth position of the paired-domain. The Pax-3Delta prd construct lacks an XmaI fragment (positions 342-672 in the Pax-3 cDNA) which encodes amino acids 17-126 of the Pax-3 polypeptide and includes the first 92 residues of the paired-domain. Several other point mutations were created using the polymerase chain reaction with mutagenic oligonucleotide primers that replace either the codon for glycine at position 9 of the paired-domain with codons for cysteine, glutamate, and proline (primers Pax-3C9, E9, and P9 listed below), or that introduce an alanine codon at positions 6-10 of the Pax-3 paired-domain (primers Pax-3A6-A10 listed below). The mutagenic primer was used in combination with a second oligonucleotide primer (5'-CTGTCTCCTGGTACCTGCAC-3', positions 577-558) and restriction digestion of the resulting polymerase chain reaction product produced a MscI-KpnI (positions 396 and 563 in the Pax-3 cDNA, respectively) restriction fragment that could be used to replace the corresponding portion of the wild-type Pax-3 XmaI fragment present in pBluescript (Stratagene). After verifying the sequence integrity of polymerase chain reaction products by dideoxy nucleotide sequencing, the XmaI cassette was cloned into the unique XmaI site of the Pax-3Delta prd expression construct. The sequence of the oligonucleotides used for mutagenesis is listed below. In each case, the oligonucleotide is anchored at the 5' end to position 399 of the Pax-3 cDNA (21) and the mutagenized codon is underlined: Pax-3C9, 5'-CCAAGGCCGAGTCAACCAGCTCTGCGGAGTA-3'; Pax-3E9, 5'-CCAAGGCCGAGTCAACCAGCTCGAAGGAGTA-3'; Pax-3P9, 5'-CCAAGGCCGAGTCAACCAGCTCCCAGGAG-3'; Pax-3A6, 5'-CCAAGGCCGAGTCGCCCAGCTC-3'; Pax-3A7, 5'-CCAAGGCCGAGTCAACGCGCTCGG-3'; Pax-3A8, 5'-CCAAGGCCGAGTCAACCAGGCCGGAGG-3'; Pax-3A9, 5'-CCAAGGCCGAGTCAACCAGCTCGCAGGAGTA-3'; Pax-3A10, 5'-CCAAGGCCGAGTCAACCAGCTCGGAGCAGTAT-3'.

Expression constructs were made that contain the Pax-3 paired-domain fused to the homeodomain of human phox by stepwise addition of Pax-3 cDNA sequence to the pre-existing pCGNphox expression plasmid (22). The pCGNphox plasmid contains a cDNA fragment which encodes the 217-amino acid phox polypeptide and a 21-amino acid (MASSYPYDVPDYASLGGPRSM) amino-terminal extension that contains the influenza virus hemagglutinin A epitope (23). The addition of Pax-3 sequences involved the introduction of wild-type and Spd XmaI fragments into a unique XmaI site present in the phox cDNA within codons 3-5 (24). Additional Pax-3 sequence could be added to this plasmid using a KpnI (position 563 in the Pax-3 cDNA) to PvuII (position 985 in the Pax-3 cDNA) fragment which encodes amino acids 90-230 of Pax-3. The unique KpnI site is contained within the Pax-3 XmaI fragment and the PvuII restriction site encodes residues 12 (Gln) and 13 (Leu) in both the Pax-3 and phox homeodomains. The resulting plasmids, phoxPDG9 and phoxPDR9, encode polypeptides of 330 amino acids with a predicted molecular mass of approximately 37 kDa. A final chimeric construct was synthesized that lacks amino acids 17-126 of Pax-3 by removal of the XmaI fragment as described above for Pax-3Delta prd.

Expression and Detection of Pax-3 in COS-7 Cells

COS-7 cells were maintained in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum at 37 °C under 5% CO2. Approximately 1.5 × 106 COS-7 cells were transfected by calcium-phosphate co-precipitation (25) using 20 µg of supercoiled plasmid DNA prepared by CsCl equilibrium density centrifugation. Precipitates were left on cells for 16 h, at which time the cells were washed once with phosphate-buffered saline, and then treated for 1 min with 15% glycerol in 1 × HEPES-buffered saline (2 × HBS is 280 mM NaCl, 10 mM KCl, 1.5 mM Na2HPO4·2H2O, 12 mM dextrose, and 50 mM HEPES, pH 7.05) at 37 °C. Whole cell extracts were prepared 24 h later by sonication in 200 µl of ice-cold buffer containing 20 mM HEPES (pH 7.6), 150 mM NaCl, 0.5 mM dithiothreitol, 0.2 mM EDTA, 0.2 mM EGTA, and protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, 1 µg/ml aprotinin, and 1 µg/ml pepstatin) (19, 26). The level of Pax-3 expression was determined by Western blotting using a polyclonal anti-Pax-3 antibody (19) at a 1:5000 dilution and visualized by enhanced chemiluminescence using a donkey anti-rabbit horseradish peroxidase-conjugated secondary antibody (Amersham). Similarly, the level of protein expression from the pCGN plasmids was determined using a monoclonal anti-HA antibody (12CA5, BAbCO) at a 1:1000 dilution and a sheep anti-mouse horseradish peroxidase-conjugated secondary antibody (Amersham).

Electrophoretic Mobility Shift Analysis

Whole cell extracts were added to 5 fmol of 32P-labeled oligonucleotide in a 20-µl reaction volume containing 10 mM Tris-HCl (pH 7.5), 2 mM MgCl2, 50 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, and 5% glycerol (27). In addition, when using the P3OPT oligonucleotide, 1 µg each of p(dI·dC)-p(dI·dC) and sonicated salmon sperm DNA was added as a nonspecific competitor, whereas 2 µg of sonicated salmon sperm DNA was added when the P1/2, P2, and P3 oligonucleotides were used. Protein-DNA complexes were allowed to form at 20 °C for 30 min, and were then loaded onto 6% polyacrylamide:bisacrylamide (29:1) gels containing 0.5 × TBE (90 mM Tris-HCl, 90 mM boric acid, 2 mM EDTA, pH 8.3), and electrophoresed at 12 V/cm in the same buffer. Gels were dried under vacuum and exposed to a PhosphorImager screen (Fuji) so that quantitation of radioactivity could be done using a Fuji BAS 2000 PhosphorImaging station and then to Kodak XAR-5 film with an intensifying screen.

Several oligonucleotides were used in electrophoretic mobility shift assays to detect either paired-domain or homeodomain DNA binding activity. The P3OPT oligonucleotide was derived from optimal recognition sequences determined for the Pax-3 paired-domain in vitro (28, 29) and contains the core sequence 5'-[N]11GTCACGCTT[N]8-3'. In addition, to reduce nonspecific binding to the P3OPT oligonucleotide, a 20-fold excess of unlabeled P3OPT was added. Oligonucleotides specific for homeodomain DNA binding were previously identified by the SELEX procedure (17) and include P1/2 (5'-[N]11TAATTGAGCG[N]8-3'), P2 (5'-[N]11TAATT-GATTA[N]8-3'), and P3 (5'-[N]11TAATTGGATTA[N]8-3'). Oligonucleotides were synthesized to have a recessed 3' end that would permit end labeling with [alpha -32P]dATP and Klenow DNA polymerase upon annealing.


RESULTS

Mutagenesis at Position 9 of the Pax-3 Paired-domain

The Spd mutation involves an arginine for glycine substitution at the ninth position of the Pax-3 paired-domain (30). Based on the three-dimensional crystal structure solved for the paired-domain of the Drosophila Prd protein, this conserved glycine residue is situated in a beta -turn (tau 1, Fig. 1A) that connects two anti-parallel beta -strands (beta 1 and beta 2, Fig. 1A), forming a beta -hairpin motif at the amino terminus of the protein. This motif makes three phosphate contacts and also contributes to stabilizing the adjacent helix-turn-helix motif (alpha 2 and alpha 3, Fig. 1A), and a second beta -turn (tau 2, Fig. 1A) that occupies the minor groove (20). Consequently, disruption of the beta -turn is expected to have a profound effect on DNA binding by the paired-domain as we have previously shown (19). Interestingly, the Spd mutation was also found to decrease the homeodomain-specific DNA binding activity of Pax-3 and suggested that the paired-domain and homeodomain may functionally interact within the full-length protein (19). An alternative explanation to this surprising relationship is that the Spd mutation disturbs folding of the Pax-3 polypeptide in a manner that does not reflect normal interactions within the wild-type protein. Therefore, it was important to distinguish between a specific structural requirement for Gly-9 in the beta -turn and any nonspecific effects attributed to substitution with arginine. To accomplish this, the glycine residue was independently replaced with glutamate, cysteine, and proline to evaluate the role of amino acid charge, size, flexibility, and hydrophobicity in the Spd DNA-binding defect (summarized in Fig. 1B).


Fig. 1. Mutagenesis at position 9 of the Pax-3 paired-domain and its effect on DNA binding activity. A, schematic representation of the paired-domain three-dimensional structure. The NH2-terminal subdomain is shown and comprises three alpha -helices (alpha 1-alpha 3), the last two of which form a helix-turn-helix motif, and a beta -hairpin structure that contacts the phosphate backbone. B, summary of mutagenic strategy and its effect on protein secondary structure. The amino acid sequence is shown for residues 1-32 of the Pax-3 paired-domain and the secondary structure is shown schematically in the upper panel (beta , beta -strand; tau , beta -turn; alpha , alpha -helix). Residues 4-12 make up the beta -hairpin motif. The mutagenesis at position 9 involves substitution with R (arginine), C (cysteine), E (glutamate), and P (proline), and the location of conserved residues is indicated (cons). The effect of mutagenesis on protein secondary structure was examined using the computer program nnpredict in the lower panel. The predicted location of the 2 beta -strands (E) and the first alpha -helix (H) is shown for wild-type Pax-3 and each of the position 9 mutants. C, immunodetection of Pax-3 in COS-7 whole cell extracts. Proteins were resolved by 12% SDS-PAGE, transferred to nitrocellulose, and Pax-3 was detected by enhanced chemiluminescence using an anti-Pax-3 polyclonal antibody and a horseradish peroxidase-conjugated donkey anti-rabbit secondary antibody (Amersham). D, EMSA of position 9 mutants using the paired-domain specific oligonucleotide P3OPT. Protein-DNA complexes were resolved by 6% native PAGE in 0.5 × TBE. The location of the specific Pax-3 complex is indicated (open arrow), and the free probe is shown (closed arrow). E, EMSA of position 9 mutants using the homeodomain-specific oligonucleotide P2. Complexes were resolved as described above and include both Pax-3 monomers (lower open arrow) and dimers (upper open arrow). The location of the unbound P2 oligonucleotide is indicated (closed arrow).
[View Larger Version of this Image (39K GIF file)]

Wild-type Pax-3 and position 9 mutants were expressed in COS-7 cells and Pax-3 protein expression was measured by Western blotting using a Pax-3 specific antiserum (Fig. 1C). This analysis indicated that similar amounts of Pax-3 protein were present in the whole cell extracts corresponding to each of the transfectants, and equivalent amounts of wild-type and mutant proteins were therefore used in electrophoretic mobility shift assays (EMSAs). Using the paired-domain specific oligonucleotide P3OPT, it is apparent that the Spd substitution (R9) leads to a complete loss of paired-domain DNA binding activity (compare lanes 1 and 2, Fig. 1D). Results from binding studies with P3OPT are consistent with those previously obtained using the e5 sequence from the Drosophila even-skipped promoter, where a 17-fold reduction in binding was observed (19). Interestingly, mutation to glutamate also ablates paired-domain DNA binding activity (lane 3 in Fig. 1D), indicating that the net charge of the substituted amino acid is not important in this phenotype. Similarly, substitution with cysteine, which contains a polar but uncharged side chain, abrogates paired-domain DNA binding activity. Furthermore, since glutamate and cysteine have smaller side chains than arginine and can adopt fewer conformations, loss of binding by these mutants suggests that the size of the substituted amino acid is not an important determinant in the loss of paired-domain DNA binding in Spd. The only mutant that does form a detectable complex with the P3OPT oligonucleotide is proline (lane 5, Fig. 1D), although it is characterized by an approximately 20-fold lower affinity than wild-type Pax-3 (lane 1, Fig. 1D). Given that proline is the only substitution that may allow the beta -turn to form (modeling data not shown), this analysis would suggest that the Spd mutation acts primarily through the disruption of this structure.

Is this structural defect also the basis for the loss in homeodomain DNA binding activity? To answer this, the same series of mutants was analyzed in EMSAs using a consensus oligonucleotide derived for homeodomains of the paired class (P2) (17). As we have shown previously, the Spd arginine substitution reduces binding to the P2 oligonucleotide approximately 20-fold when compared with wild-type Pax-3 (compare lanes 1 and 2, Fig. 1E). Likewise, both the glutamate (lane 3, Fig. 1E) and cysteine (lane 4, Fig. 1E) mutations cause an approximately 20-fold reduction in P2 binding. Substitution with proline resulted in a mutant that retained approximately 10% of its homeodomain DNA binding activity (lane 5, Fig. 1E). As was observed with P3OPT, the lack of any correlation between amino acid charge, size, or hydrophobicity with the defect in P2 binding, and the reduced severity of the proline substitution indicate that the loss of the beta -turn is also responsible for the reduction in homeodomain DNA binding activity.

Alanine Replacement Mutagenesis at Positions 6-10 of the Pax-3 Paired-domain

The beta -turn is an essential component of the beta -hairpin motif (Fig. 1A). Within the beta -hairpin motif, residues 6-10 are perfectly conserved in all paired-domains described to date which suggests that they are essential for paired-domain function (Fig. 2A). As a result, these residues were chosen for independent alanine replacement to further define the requirement for the beta -hairpin in DNA binding by Pax-3. For this, the last residue in the first beta -strand (Asn-6), the three residues which make up the beta -turn (Gln-7, Leu-8, and Gly-9), and the first residue (Gly-10) of the second beta -strand were individually mutated to alanine (summarized in Fig. 2A). With the exception of Gln-7, alanine replacement at each position is predicted to alter the local secondary structure (lower panel in Fig. 2A), and should therefore affect the functionality of the beta -hairpin motif. To visualize the role of these amino acids within the beta -hairpin motif and the possible impact of their replacement with alanine, the location of side chains is shown schematically with respect to the alpha -carbon trace in Fig. 2B. The side chains for Asn-6 and Leu-8 are both directed toward the helix-turn-helix structure (HTH), which binds in the adjacent major groove (refer also to Fig. 1B). Similarly, replacement of the hydrogen R-group of Gly-10 with the methyl R-group of alanine would occur in the interface with the HTH motif and, as a result, the effect of these substitutions may not be confined to the beta -hairpin. In contrast, substitution of the Gly-9 and Gln-7 side chains occurs on the solvent exposed surface of the beta -hairpin structure. Consequently, the individual mutations are likely to affect the overall structure of the beta -hairpin in different ways.


Fig. 2. Alanine scanning mutagenesis of positions 6-10 of the Pax-3 paired-domain and their effect on DNA binding activity. A, summary of mutagenic strategy and its effect on protein secondary structure. The location of alanine replacement mutants (A6-A10) is shown with respect to their location in the Pax-3 paired-domain and to the secondary structure features (upper panel). The predicted effect of these mutants on secondary structure was determined using the computer program nnpredict (lower panel) and, with the exception of the A7 mutant, each is expected to perturb the local structure. B, schematic representation of the beta -hairpin structure. The location of amino acid side chains for residues 6-10 is shown with respect to the alpha -carbon trace (prepared using InsightII). C, immunodetection of Pax-3 in COS-7 whole cell extracts. Proteins were resolved by 12% SDS-PAGE, transferred to nitrocellulose, and Pax-3 was detected by enhanced chemiluminescence using an anti-Pax-3 polyclonal antibody and a horseradish peroxidase-conjugated donkey anti-rabbit secondary antibody (Amersham). D, EMSA of wild-type Pax-3 and alanine scanning mutants using the paired-domain specific oligonucleotide P3OPT. The protein extract used is indicated above each lane (WT, A6-A10). Protein-DNA complexes were resolved by 6% native PAGE in 0.5 × TBE. The location of the specific Pax-3 complex is indicated (open arrow) and the free probe is shown (closed arrow). A nonspecific complex in the wild-type reaction is also indicated (asterisk). E, EMSA of wild-type Pax-3 and alanine scanning mutants using the homeodomain-specific oligonucleotide P2. Complexes were resolved as described above and include both Pax-3 monomers (lower open arrow) and dimers (upper open arrow). The location of the unbound P2 oligonucleotide is indicated (closed arrow).
[View Larger Version of this Image (45K GIF file)]

Each of the alanine-substituted proteins was expressed in COS-7 cells and Pax-3 levels were determined by Western blotting, revealing similar amounts of Pax-3 polypeptide in each whole cell extract (Fig. 2C). Equivalent amounts of Pax-3 protein were then used in EMSAs with the paired-domain specific oligonucleotide P3OPT (Fig. 2D). In this analysis, the mutants can be categorized into three groups based on the extent to which they reduce paired-domain DNA binding. The first, which includes substitutions of Asn-6, Leu-8, and Gly-9, do not form a detectable complex with the P3OPT oligonucleotide when compared with wild-type Pax-3 (compare lanes 2, 4, and 5 to lane 1, Fig. 2D). The drastic loss of binding by the Gly-9 mutant further illustrates the strict requirement for the beta -turn in paired-domain function, in agreement with arginine, glutamate, and cysteine substitutions at that position (Fig. 1). The next category involves replacement of Gly-10, which leads to only an approximately 8-fold reduction in P3OPT binding (lane 6, Fig. 2D) and may reflect the more conservative nature of this substitution in the second beta -strand. Last, substitution of Gln-7 causes no obvious defect in paired-domain DNA binding activity (lane 3, Fig. 2D), despite the fact that the side chain of Gln-7 makes a phosphate contact in the paired-domain crystal structure (20), suggesting that this contact is not essential for docking of the paired domain on DNA.

The alanine scanning mutants were then tested with the P2 oligonucleotide to determine the impact of these mutations on Pax-3 homeodomain DNA binding activity (Fig. 2E). Alanine replacement at Asn-6 and Gly-9 decreased binding to the P2 oligonucleotide approximately 20-fold (lanes 2 and 5, Fig. 2E), whereas mutation of Leu-8 causes an approximately 5-fold reduction in homeodomain DNA binding activity (lane 4, Fig. 2E) when each is compared with wild-type Pax-3 (lane 1, Fig. 2E). In addition, the Gly-10 mutant which retained partial paired-domain DNA binding activity also has a higher degree of homeodomain DNA binding activity when compared with mutations at positions 6, 8, and 9 (compare lane 6 to lanes 2, 4, and 5 in Fig. 2E), although it is still 2-fold lower than the wild-type Pax-3 protein (lane 1 in Fig. 2E). As was observed with P3OPT, alanine replacement of Gln-7 also displays a wild-type level of homeodomain DNA binding activity (lane 3 in Fig. 2D). The same results were obtained with an independent series of whole cell extracts. This analysis reveals that mutations at other positions within the beta -hairpin motif of the paired-domain can cause defects in binding by the Pax-3 homeodomain, and is consistent with our original hypothesis that the two domains functionally interact. Importantly, the general correlation between paired-domain and homeodomain DNA binding properties in this mutagenic analysis suggests that the beta -hairpin is essential for the DNA binding activity of both domains.

Paired-domain Mutations Affect Monomeric Binding by the Pax-3 Homeodomain

In the analyses described above, the DNA binding properties of the Pax-3 homeodomain were investigated using the P2 oligonucleotide as it represents the consensus binding sequence for paired class homeodomains containing a serine at position 50 (17). In this case, dimerization by the homeodomain occurs with 30-40-fold cooperativity over monomeric binding and, accordingly, the predominant complex formed by the position 9 and alanine scanning mutants appears to be the slower migrating dimeric form (Fig. 1E and Fig. 2E). It was therefore important to distinguish between a requirement for the beta -hairpin structure in monomeric binding by the homeodomain from any effects the disruption of this structure could have on dimerization. To address this issue, the monomeric homeodomain binding properties of position 9 and alanine-replacement mutants were characterized using an oligonucleotide which contains a single TAAT motif (P1/2) (Fig. 3).


Fig. 3. Effect of position 9 and alanine scanning mutants on monomeric binding by the homeodomain. An EMSA using the wild-type, position 9, and alanine scanning mutants with the homeodomain-specific oligonucleotide P1/2 is shown. The P1/2 oligonucleotide contains a single TAAT motif and only supports monomer binding by the homeodomain. A comparison of P2 and P1/2 binding to Pax-3 is shown in the left panel, where the P1/2 oligonucleotide only forms the faster migrating monomeric complex. In the right panel, the P1/2-binding properties of the position 9 and alanine scanning mutants is shown. The location of the specific monomeric complex formed by Pax-3 and Pax-3A7 is indicated with an open arrow, while the location of free probe is shown with a closed arrow. Protein-DNA complexes were resolved by 6% native PAGE in 0.5 × TBE.
[View Larger Version of this Image (42K GIF file)]

The difference in Pax-3 binding to P1/2 and P2 is illustrated in Fig. 3A where the single, lower-affinity complex formed with the P1/2 oligonucleotide (lane 2) corresponds to the faster migrating of the two complexes observed with the P2 oligonucleotide (lane 1). Comparing the P1/2 binding activities of wild-type Pax-3 to the R9, C9, E9, and P9 mutants (compare lane 3 to lanes 4-7 in Fig. 3), a clear defect in formation of the P1/2 complex can be observed. Furthermore, alanine replacement of Asn-6, Leu-8, Gly-9, and Gly-10, which all exhibited greatly reduced binding to both P3OPT and P2 (Fig. 2, D and E), do not interact with the P1/2 oligonucleotide at a detectable level (lanes 8, 10, 11, and 12 in Fig. 3). On the other hand, substitution of Gln-7 with alanine did not affect P1/2 binding activity (lane 9, Fig. 3), consistent with its wild-type binding properties on P3OPT and P2. These results indicate that disruption of the beta -hairpin motif affects monomeric binding by the Pax-3 homeodomain and does not represent a defect in the ability of the Pax-3 homeodomain to dimerize.

Transfer of the Spd Defect to a Heterologous Homeodomain

Is the requirement of the beta -hairpin structure for homeodomain DNA-binding a unique property of the Pax-3 homeodomain? To address this question, a chimera was constructed which fused the Pax-3 paired-domain and linker region to the human phox homeodomain. The phox homeodomain was chosen as it displays a reasonably high degree of identity to the Pax-3 homeodomain (67%), yet it normally functions without a paired-domain (24). Furthermore, the presence of a glutamine residue at position 50 of the phox homeodomain confers DNA binding properties that are distinct from those dictated by the serine present at this location in the Pax-3 homeodomain (17, 31). The chimera involved the replacement of amino acids 22 to 107 of pCGNphox with a region comprising amino acids 18-230 from Pax-3 (Fig. 4A). In addition, the pCGN expression constructs encodes an epitope for hemagglutinin A (HA) at their amino termini. The wild-type phox and chimeric constructs were expressed in COS-7 cells and proteins were detected by Western blotting using a monoclonal anti-HA antibody (Fig. 4B). The size of the proteins detected by the antibody corresponds to those predicted from the primary sequence of phox (25 kDa) and the Pax-3 chimeras (37 kDa) and indicates that the wild-type (phoxPDG9) and Spd (phoxDPR9) chimeras are expressed at similar levels (Fig. 4B).


Fig. 4. Transfer of the Spd defect to a heterologous homeodomain. A, schematic representation of Pax-3, phox, and chimeric proteins. The Pax-3 and phox proteins comprise 479 and 217 amino acids, respectively. The two polypeptides exhibit no homology outside of the homeodomain. The chimera involves replacement of residues 22-102 in phox with amino acids 18-230 of Pax-3, including the entire Pax-3 paired-domain, and the junction is located within the amino terminus of helix 1 of the phox homeodomain (stippled, alpha -helices are shown as small open boxes). B, immunodetection of phox and chimeric proteins in COS-7 whole cell extracts. Proteins were resolved by 12% SDS-PAGE and transferred to nitrocellulose. Each of the recombinant phox proteins contains an epitope derived from Haemophilus influenza hemagglutinin A (HA-tag) at its amino terminus allowing their detection with a monoclonal anti-HA antibody (BAbCO) and a horseradish peroxidase-conjugated sheep anti-mouse antibody by enhanced chemiluminescence (Amersham). Adjacent lanes represent 2-fold increases in protein concentration. C, EMSAs of phox, phoxPDG9, and phoxPDR9 using the P1/2 oligonucleotide. In each dilution series, adjacent lanes represent a 2-fold increase in protein concentration. The location of the specific monomeric complex (open arrow) and the free probe (closed arrow) are indicated. Protein-DNA complexes were resolved by 6% native PAGE in 0.5 × TBE.
[View Larger Version of this Image (28K GIF file)]

The DNA binding characteristics of the wild-type phox and chimeric proteins were then analyzed by EMSA using the P1/2 oligonucleotide (Fig. 4C). The wild-type phox protein binds to the P1/2 oligonucleotide with high affinity as expected, as does the phoxPDG9 chimera (compare lane 1 to lanes 2 and 3, Fig. 4C). However, the phoxPDR9 chimera, which harbors the Spd mutation, shows an approximately 20-fold loss in P1/2 binding activity (lanes 4 and 5, in Fig. 4C) when compared with the phoxPDG9 chimera and wild-type phox. Therefore, the requirement for the beta -hairpin motif at the level of monomer binding can be transferred to a heterologous homeodomain.

The Pax-3 Paired-domain Affects the Sequence Specificity of the Homeodomain

Paired-class homeodomains have been shown to bind to palindromic TAAT motifs separated by 2- (P2) or 3-base pair spacers (P3), and the homeodomain of Drosophila Prd binds P2 and P3 sequences with similar affinity and cooperativity (17). To further characterize the effect of the paired-domain on homeodomain DNA binding, we monitored the effect of wild-type or mutant paired-domains on homeodomain binding to P3 in the context of the full-length Pax-3 protein (Fig. 5). Interestingly, EMSAs of wild-type Pax-3 on the P3 oligonucleotide (lane 3 and 4, Fig. 5A) only detected the lower affinity monomeric complex upon comparison to complexes formed with the P2 oligonucleotide (lanes 1 and 2, Fig. 5A) when using a fixed amount of Pax-3 and oligonucleotides labeled to the same specific activity. In addition, the P3 DNA binding properties of position 9 and alanine scanning mutants (data not shown) were identical to those observed with the P1/2 oligonucleotide (Fig. 3). To determine if this inability to dimerize on the P3 oligonucleotide derives from the presence of the paired-domain or simply represents an inherent property of the Pax-3 homeodomain, the P3 binding properties of a protein (Pax-3Delta prd) lacking the first 92 amino acids of the paired-domain were investigated. Results shown in Fig. 5B indicate that Pax-3Delta prd can dimerize to the same extent on P2 (lane 3) and P3 oligonucleotides (lane 4), whereas intact Pax-3 can only dimerize on P2 (compare lanes 1 and 2, Fig. 5B). Therefore, the presence of the paired-domain in the Pax-3 protein precludes dimerization of the homeodomain on the P3 oligonucleotide.


Fig. 5. The Pax-3 paired-domain impairs homeodomain dimerization on P3-motifs. A, EMSA of Pax-3 with P2 and P3 oligonucleotides. The presence of dimeric complexes in reactions containing P2 is indicated (open arrowheads) and the location of the single complex formed with the P3 oligonucleotide is shown by an arrow. The protein concentration differs by 2-fold in adjacent lanes. B, EMSA comparing Pax-3 and Pax-3Delta prd binding to the P2 and P3 oligonucleotides. The protein extract used in each reaction is indicated above the autoradiogram and the oligonucleotide is identified below, and the location of monomeric and dimeric complexes are shown by open arrowheads. C, EMSA of Pax-3, phox, and chimeric proteins using a Pax-6-derived P3 oligonucleotide. In each case, the protein extract used is indicated above the autoradiogram and the oligonucleotide probe is listed below. The Pax-6-derived P3 oligonucleotide is denoted as P3.S. The location of monomeric and dimeric complexes is indicated by open arrows for both Pax-3 and the series of phox proteins. D, comparison of P3 sequences. The sequence of the P2 and P3 oligonucleotide is shown and differ by the presence of a single dG residue in the spacer region. The substitutions or deletions present in the P3.3, P3.5, and P3.S oligonucleotides are also shown, and each oligonucleotide contains a consensus TAAT(N)2-3ATTA motif; only the half-sites and spacer sequence are shown. E, EMSA of phox, phoxPDG9, and phoxDelta prd using the P3, P3.3, and P3.5 oligonucleotides. The extract present in each reaction is indicated above the autoradiogram and the oligonucleotide used is identified below. Specific complexes are indicated by open arrowheads. Protein-DNA complexes were resolved by 6% native PAGE in 0.5 × TBE.
[View Larger Version of this Image (55K GIF file)]

The failure of Pax-3 to dimerize on the P3 oligonucleotide was somewhat surprising given that in vitro selection of consensus motifs for the closely related Pax-6 homeodomain revealed its preference for a P3-based motif (32). The Pax-6 derived P3 oligonucleotide was therefore used in EMSAs with Pax-3 to determine if its unique sequence composition affected the ability of Pax-3 to dimerize. Remarkably, this oligonucleotide shows a complete failure to bind to the Pax-3 homeodomain when compared with P2 (compare lanes 1 and 2, Fig. 5C). This result is even more striking when using phox, phoxPDG9, and phoxDelta prd (lanes 3-8, Fig. 5C) for the following reason: the presence of glutamine at position 50 of the phox homeodomain allows it to dimerize with approximately 10-fold greater cooperativity on P3 motifs than paired-class homeodomains containing a serine at this position (17, 31). Despite this difference, the phoxPDG9 chimera fails to bind to the Pax-6 derived P3 oligonucleotide (lane 6, Fig. 5C) when compared with its binding to P2 as a control (lane 3, Fig. 5C). Moreover, the ability of both the phox and phoxDelta prd proteins to efficiently dimerize on this oligonucleotide (lanes 7 and 8, Fig. 5C), when compared with their monomeric binding to P2 (lanes 4 and 5, Fig. 5C), indicates that the presence of the paired-domain is responsible for the failure of the phox homeodomain to bind the Pax-6-derived P3 sequence effectively.

The Pax-6-derived oligonucleotide (P3.S in Fig. 5D) differs from the original P3 sequence in several ways: it only contains 4 base pairs flanking the palindromic homeodomain recognition site, and both the flanking and spacer sequences differ from that of P2 and P3 (Fig. 5D). To determine if such differences impact upon sequence recognition in the presence of the paired-domain, a series of P3-based oligonucleotides were synthesized that involved the stepwise replacement of sequences in P3.S with those present in P3 (P3.3 and P3.5 in Fig. 5D). In this analysis, the phox homeodomain was chosen because of its greater propensity to dimerize on P3-type sequences. Accordingly, the predominant complex formed between phox and the P3, P3.5, and P3.3 oligonucleotides is dimeric (lanes 1-3, Fig. 5E), and the slightly lower affinity of P3.5 and P3.3 can be attributed to the presence of a non-consensus purine residue following the TAAT motif on the complementary strand (17). As was observed with P3.S (lane 6, Fig. 5C), the phoxPDG9 chimera also fails to bind the P3.5 and P3.3 oligonucleotides (lanes 5 and 6, Fig. 5C). In contrast, phoxPDG9 does bind to the P3 oligonucleotide efficiently (lane 4, Fig. 5E) and indicates that the differences in the spacer sequence between P3 and P3.3 can account for the loss of homeodomain DNA-binding. However, the sequence differences present in these P3 oligonucleotides do not restore homeodomain dimerization to the phoxPDG9 chimera, and this is consistent with the behavior of Pax-3 (Fig. 5C and data not shown). Finally, the restoration of dimerization on P3, P3.3, and P3.5 by deletion of the paired-domain in phoxDelta prd (lanes 7-9, Fig. 5E) indicates that it is indeed the paired-domain which confers these additional sequence constraints and prevents homeodomain dimerization on P3-based sequences.


DISCUSSION

The paired-domain has been highly conserved throughout evolution and defines the nine members of the mammalian Pax gene family (3). Like Prd and the two gene products of the Drosophila gooseberry locus, the murine Pax-3, -4, -6, and -7 proteins also contain a homeodomain. In the Caenorhabditis elegans PAX-6 gene, alternative transcript initiation creates two mRNAs that encode proteins containing both domains, or only the homeodomain (33, 34). Hence, the presence of the paired-domain and homeodomain in separate polypeptides would indicate that they can function independently. In addition, when expressed separately, the paired-domain (20, 28, 35) and homeodomain (17) bind to distinct, in vitro-derived consensus sequences with high affinity, allowing the crystallization of the DNA-bound complexes (20, 36), which would seem to establish their structural independence. Despite this apparent independence, rescue of paired null mutants requires the presence of both domains within the same polypeptide and mutations in either domain cause similar phenotypes (37). Likewise, mutations in the paired-domain or homeodomain of human PAX-3 both give rise to Waardenburg Syndrome type I (38), suggesting that each domain is necessary for normal Pax-3 function. At the biochemical level, this possibility was suggested by analysis of the mouse Pax-3 Spd mutant in which a glycine-arginine substitution within the paired-domain abrogates the DNA binding activity of both domains (19). The current study extends this observation and establishes that the integrity of the beta -hairpin motif in the Pax-3 paired-domain is necessary for DNA binding by both the paired-domain and homeodomain. An important consequence of their presence in the same polypeptide is that the recognition of sequences that would normally be bound by the homeodomain is impaired by the presence of the paired-domain and this is likely to affect sequence recognition by the Pax-3 homeodomain in vivo.

Crystallization of the paired-domain of Drosophila Prd identified two globular subdomains, NH2-terminal and COOH-terminal, each of which contains three alpha -helices that form a classical HTH motif (20). In addition, the NH2-terminal subdomain is characterized by a novel beta -hairpin motif that comprises 2 anti-parallel beta -strands that are separated by a 3-amino acid beta -turn, and this motif contributes extensively to the overall docking of the paired-domain on DNA. The 2 beta -strands clamp the DNA-phosphate backbone and stabilize a second beta -turn which engages the DNA minor groove, and the beta -hairpin also interacts with the HTH motif that occupies the major-groove adjacent to the phosphate clamp (Fig. 1A). In Spd, the arginine mutation replaces a glycine residue that is necessary for the maintenance of the beta -turn, and its disruption would most likely affect the function of the beta -hairpin as a whole, accounting for the abrogation of paired-domain DNA-binding. The present study establishes that replacing Gly-9 in the Pax-3 paired-domain with amino acids (Arg, Glu, Cys, and Ala) of different charge, size, flexibility, and hydrophobicity has a similar phenotypic consequence. The ability of proline to partially restore paired-domain DNA binding indicates that these mutations act primarily through disruption of the beta -turn. Furthermore, it is also clear that the defect in homeodomain binding that occurs in association with the Spd mutation involves disruption of this structure and does not simply result from the presence of a positively charged arginine residue. The integrity of the beta -turn is therefore necessary for the activity of both Pax-3 DNA-binding domains and suggests that homeodomain does not function independently within the intact protein.

Of the 9 amino acids which make up the beta -hairpin motif, only those at positions 6-10 (Asn-Gln-Leu-Gly-Gly) and 12 (Phe) are conserved in all paired-domains described to date, suggesting that they have a critical role in paired-domain function. Mutation of Asn-6 was found to severely impair DNA binding by both the paired-domain and homeodomain and identifies it as a key residue within the first beta -strand. Given that the Asn-6 side chain makes a phosphate contact and may also contribute to the stabilization of the adjacent HTH motif (20), the defect in DNA binding to the paired-domain would reflect the loss of these interactions in the presence of alanine. Substitution of Leu-8 and Gly-10 with alanine is also predicted to affect the local secondary structure, and may disturb the interaction with the HTH motif where their side chains normally reside (20). Consistent with this prediction, the Leu-8 mutant has no detectable paired-domain DNA binding activity, although it does retain a fraction of its homeodomain DNA binding activity. The Gly-10 substitution exhibits even greater homeodomain DNA binding activity and detectable binding to the paired-domain, in keeping with the more conservative nature of alanine replacement at position 10. Interestingly, substitution of Gln-7 has no apparent effect on DNA binding by either domain. Although the presence of alanine is not expected to disrupt the secondary structure and would still allow contact with the phosphate backbone through the peptide bond amide group, the Gln-7 side chain normally makes an additional phosphate contact (20). It therefore seems apparent that this contact is not essential for docking of the paired-domain on DNA, although it is possible that the Gln-7 mutant may reduce binding to suboptimal paired-domain recognition motifs where the phosphate contact makes a greater overall contribution to DNA binding. These data suggest that the structural requirement at this position is more important than the phosphate contact for DNA binding. Significantly, the correlation between paired-domain and homeodomain DNA binding activities indicates that the integrity of the beta -hairpin is important for DNA binding by both domains, supporting the notion of an underlying functional interdependence.

The derivation of optimal binding sequences for paired-class homeodomains established that they cooperatively dimerize on TAAT(N)2-3ATTA motifs (17). Consequently, analyses using the P2 oligonucleotide do not resolve the effect of paired-domain mutations on monomer or dimer binding. It was therefore possible that disruption of a specific paired-domain structure could have a deleterious effect on homeodomain dimerization and not on homeodomain DNA binding per se. However, the nature of this requirement was resolved by establishing that mutations which reduce paired-domain DNA binding activity impair monomer binding by the Pax-3 homeodomain (Fig. 3). The transfer of the Spd defect to the phox homeodomain confirms this finding and also establishes that a heterologous homeodomain can be rendered functionally dependent on the paired-domain. In addition, the recent characterization of the Drosophila even-skipped gene has identified a regulatory element that requires the cooperative binding of the paired-domain and homeodomain of Prd to function (18). Although this establishes that the paired-domain and homeodomain can cooperate in DNA binding, our analyses suggest that the two domains cannot function independently, but must cooperate to enable homeodomain DNA binding.

How is this functional dependence expected to affect sequence recognition by the Pax-3 homeodomain? A possible answer comes with the finding that wild-type Pax-3 failed to dimerize on a series of oligonucleotides that comprise a palindromic homeodomain recognition motif with a 3-base pair spacer (P3) (Fig. 5 and data not shown). The fact that deleting the paired-domain restores dimer formation on P3 oligonucleotides is both consistent with previous analyses in which the isolated paired homeodomain exhibited similar cooperativity on P2 and P3 sequences (17), and suggests that the paired-domain precludes dimer formation on P3 motifs. This possibility is made even more likely with the analysis of the phox chimera for the following reason: the presence of glutamine at position 50 of the phox homeodomain enables much higher cooperativity on P3 sequences than serine 50 homeodomains, which typically exhibit only 40-fold cooperativity (17). Despite this enhanced dimerization potential, the presence of the paired-domain in the phox chimera completely prevents dimerization. This behavior is also supported by the results of in vitro oligonucleotide selection using a Prd polypeptide that contained both a paired-domain and homeodomain (39), or the homeodomain alone (17). Although both assays lead to the identification of the P2 sequence, the P3 motif was no longer selected when the paired-domain was present (39). This suggests that P3 motifs may not be efficiently recognized by Pax proteins in vivo, and that the interactions which allow dimerization of intact Pax-3 on P2 sequences must be fundamentally different than those defined in the crystal structure of the Prd homeodomain complexed to a P3 oligonucleotide.

Although the underlying mechanism involved in the cooperative interaction of the Pax-3 paired-domain and homeodomain remains to be defined, our findings parallel those involving other homeodomains, in which interactions with a second DNA-binding domain are required to confer appropriate target gene specificity. In the case of the yeast MAT-a1 and MAT-alpha 2 proteins, this specificity arises through the binding of a MAT-alpha 2-derived amphipathic alpha -helix to the MAT-a1 homeodomain (40). In isolation, the MAT-a1 homeodomain has no specific DNA binding activity (41). Similarly, a hydrophobic pentapeptide motif present in certain Hox proteins is required for cooperative interaction with a second homeodomain-containing protein, Pbx1 (42). Despite each of these examples being mechanistically different, such functional interactions invariably confer novel sequence specificity to the DNA-binding partner, and are likely to play an important role in selection of target sequences by Pax-3 in vivo.


FOOTNOTES

*   This work was supported in part by a grant from the Medical Research Council of Canada (to P. G.).The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§   Recipient of a scientist award from the Medical Research Council of Canada. To whom correspondence should be addressed: Dept. of Biochemistry, McIntyre Medical Sciences Building, McGill University, 3655 Drummond St., Montreal, Quebec, H3G 1Y6 Canada. Tel.: 514-398-7291; Fax: 514-398-2603; E-mail: gros{at}medcor.mcgill.ca.
1   The abbreviations used are: Prd, paired; Spd, Splotch-delayed; EMSA, electrophoretic mobility shift assay; HTH, helix-turn-helix; PD, paired-domain; PAGE, polyacrylamide gel electrophoresis.

ACKNOWLEDGEMENTS

We thank Michael Gilman for the gift of the pCGNphox expression plasmid, Gary Leveque for technical assistance, and Kyle Vogan for helpful discussions and critical reading of the manuscript.


REFERENCES

  1. Bopp, D., Burri, M., Baumgartner, S., Frigerio, G., and Noll, M. (1986) Cell 47, 1033-1040 [Medline] [Order article via Infotrieve]
  2. Treisman, J., Harris, E., and Desplan, C. (1991) Genes Dev. 5, 594-604 [Abstract]
  3. Noll, M. (1993) Curr. Opin. Genet. Dev. 3, 595-605 [Medline] [Order article via Infotrieve]
  4. Epstein, D. J., Vekemans, M., and Gros, P. (1991) Cell 67, 767-774 [Medline] [Order article via Infotrieve]
  5. Baldwin, C. T., Hoth, C. F., Amos, J. A., da-Silva, E. O., and Milunsky, A. (1992) Nature 355, 637-638 [CrossRef][Medline] [Order article via Infotrieve]
  6. Tassabehji, M., Read, A. P., Newton, V. E., Harris, R., Balling, R., Gruss, P., and Strachan, T. (1992) Nature 355, 635-636 [CrossRef][Medline] [Order article via Infotrieve]
  7. Moase, C. E., and Trasler, D. G. (1992) J. Med. Genet. 29, 145-151 [Medline] [Order article via Infotrieve]
  8. Franz, T., Kothary, R., Surani, M. A. H., Halata, Z., and Grim, M. (1993) Anat. Embryol. 187, 153-160 [Medline] [Order article via Infotrieve]
  9. Barr, F. G., Galili, N., Holick, J., Biegel, J. A., Rovera, G., and Emanuel, B. S. (1993) Nature Genet. 3, 113-117 [Medline] [Order article via Infotrieve]
  10. Davis, R. J., D'Cruz, C. M., Lovell, M. A., Biegel, J. A., and Barr, F. G. (1994) Cancer Res. 54, 2869-2872 [Abstract]
  11. Dressler, G. R., and Douglass, E. C. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 1179-1183 [Abstract]
  12. Maulbecker, C. C., and Gruss, P. (1993) EMBO J. 12, 2361-2367 [Abstract]
  13. Stuart, E. T., Haffner, R., Oren, M., and Gruss, P. (1995) EMBO J. 14, 5638-5645 [Abstract]
  14. Czerny, T., Schaffner, G., and Busslinger, M. (1993) Genes Dev. 7, 2048-2061 [Abstract]
  15. Epstein, J. A., Glaser, T., Cai, J., Jepeal, L., Walton, D. S., and Maas, R. L. (1994) Genes Dev. 8, 2022-2034 [Abstract]
  16. Vogan, K. J., Underhill, D. A., and Gros, P. (1996) Mol. Cell. Biol. 16, 6677-6686 [Abstract]
  17. Wilson, D., Sheng, G., Lecuit, T., Dostatni, N., and Desplan, C. (1993) Genes Dev. 7, 2120-2134 [Abstract]
  18. Fujioka, M., Miskiewicz, P., Raj, L., Gulledge, A. A., Weir, M., and Goto, T. (1996) Development 122, 2697-2707 [Abstract/Free Full Text]
  19. Underhill, D. A., Vogan, K. J., and Gros, P. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 3692-3696 [Abstract/Free Full Text]
  20. Xu, W., Rould, M. A., Jun, S., Desplan, C., and Pabo, C. O. (1995) Cell 80, 639-650 [Medline] [Order article via Infotrieve]
  21. Goulding, M. D., Chalepakis, G., Deutsch, U., Erselius, J. R., and Gruss, P. (1991) EMBO J. 10, 1135-1147 [Abstract]
  22. Grueneberg, D. A., Simon, K. J., Brennan, K., and Gilman, M. (1995) Mol. Cell. Biol. 15, 3318-3326 [Abstract]
  23. Field, J., Nikawa, J., Broek, D., MacDonald, B., Rodgers, L., Wilson, I. A., Lerner, R. A., and Wigler, M. (1988) Mol. Cell. Biol. 8, 2159-2165 [Medline] [Order article via Infotrieve]
  24. Grueneberg, D. A., Natesan, S., Alexandre, C., and Gilman, M. Z. (1992) Science 257, 1089-1095 [Medline] [Order article via Infotrieve]
  25. Gorman, C., Padmanabhan, R., and Howard, B. H. (1983) Science 221, 551-553 [Medline] [Order article via Infotrieve]
  26. Chalepakis, G., Fritsch, R., Fickenscher, H., Deutsch, U., Goulding, M., and Gruss, P. (1991) Cell 66, 873-884 [Medline] [Order article via Infotrieve]
  27. Gilman, M. Z., Wilson, R. N., and Weinberg, R. A. (1986) Mol. Cell. Biol. 6, 4305-4316 [Medline] [Order article via Infotrieve]
  28. Chalepakis, G., and Gruss, P. (1995) Gene (Amst.) 162, 267-270 [CrossRef][Medline] [Order article via Infotrieve]
  29. Epstein, J. A., Lam, P., Japeal, L., Maas, R. L., and Shapiro, D. N. (1995) J. Biol. Chem. 270, 11719-11722 [Abstract/Free Full Text]
  30. Vogan, K. J., Epstein, D. J., Trasler, D. G., and Gros, P. (1993) Genomics 17, 364-369 [CrossRef][Medline] [Order article via Infotrieve]
  31. Wilson, D. S., Sheng, G., Jun, S., and Desplan, C. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 6886-6891 [Abstract/Free Full Text]
  32. Czerny, T., and Busslinger, M. (1995) Mol. Cell. Biol. 15, 2858-2871 [Abstract]
  33. Chisholm, A. D., and Horvitz, H. R. (1995) Nature 377, 52-55 [Medline] [Order article via Infotrieve]
  34. Zhang, Y., and Emmons, S. W. (1995) Nature 377, 55-59 [CrossRef][Medline] [Order article via Infotrieve]
  35. Epstein, J., Cai, J., Glaser, T., Jepeal, L., and Maas, R. (1994) J. Biol. Chem. 269, 8355-8361 [Abstract/Free Full Text]
  36. Wilson, D. S., Guenther, B., Desplan, C., and Kuriyan, J. (1995) Cell 82, 709-719 [Medline] [Order article via Infotrieve]
  37. Bertuccioli, C., Fasano, L., Jun, S., Wang, S., Sheng, G., and Desplan, C. (1996) Development 122, 2673-2685 [Abstract/Free Full Text]
  38. Baldwin, C. T., Hoth, C. F., Macina, R. A., and Milunsky, A. (1995) Am. J. Med. Genet. 58, 115-122 [Medline] [Order article via Infotrieve]
  39. Jun, S., and Desplan, C. (1996) Development 122, 2639-2650 [Abstract/Free Full Text]
  40. Li, T., Stark, M. R., Johnson, A. D., and Wolberger, C. (1995) Science 270, 262-269 [Abstract]
  41. Goutte, C., and Johnson, A. D. (1993) J. Molec. Biol. 233, 359-371 [CrossRef][Medline] [Order article via Infotrieve]
  42. Lu, Q., Knoepfler, P. S., Schelle, J., Wright, D. D., and Kamps, M. P. (1995) Mol. Cell. Biol. 15, 3786-3795 [Abstract]

©1997 by The American Society for Biochemistry and Molecular Biology, Inc.